- In December 2024, Surgeons at Royal Papworth Hospital in Cambridge performed the UK's first double-lung transplant using the XPS system by Xvivo, a novel machine that revives and maintains donor organs outside the body. This device could significantly increase the number of lungs available for transplants on the NHS, potentially saving hundreds of lives annually
- In March 2024, OrganOx, an Oxford University spin-out developing intensive care units for liver transplants, raised USD 142 million to fund its U.S. expansion and potential stock market listing. The company's technology sustains donated organs using blood at normal body temperatures and has been used in over 5,000 transplant operations since 2021
- In June 2024, Gerresheimer, a German manufacturer of drug-delivery systems, invested approximately USD 180 million to expand its production capacity in Peachtree City, Georgia, U.S. This expansion aims to enhance the production of medical systems such as inhalers and autoinjectors, strengthening its market position in North America
- In September 2024, Australia secured a USD 40 million deal to expand onshore manufacturing of IV saline fluids, crucial for medical treatments and surgeries. The federal government and Baxter Healthcare each committed USD 20 million to boost production at Baxter's western Sydney facility, aiming to produce at least 80 million units annually by 2027
- In August 2024, TransMedics Group, Inc. acquired assets and intellectual property associated with the LifeCradle Heart Preservation Transport System technology and the Ex-Vivo Organ Support System from Bridge to Life Ltd. This acquisition aims to enhance TransMedics' organ care systems, potentially improving outcomes in heart transplantation
